Kodiak Sciences (KOD) Projected to Post Quarterly Earnings on Thursday

Kodiak Sciences (NASDAQ:KOD) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Kodiak Sciences to post earnings of ($0.87) per share for the quarter.

Kodiak Sciences Stock Down 9.1 %

Shares of Kodiak Sciences stock opened at $3.20 on Wednesday. Kodiak Sciences has a 12-month low of $2.19 and a 12-month high of $11.60. The business’s 50 day moving average is $5.15 and its 200-day moving average is $5.43. The stock has a market cap of $168.40 million, a P/E ratio of -0.88 and a beta of 2.26.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 9th.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.